Reuters Japan’s Shionogi & Co said on Tuesday a global, late-stage study showed its pill-based treatment for COVID-19 was effective in reducing transmission of the disease.
Ensitrelvir, known commercially as Xocova, showed a statistically significant reduction in participants with symptomatic infection after exposure to household contacts with COVID, Shionogi said in a statement.
The Phase 3 SCORPIO-PEP trial involved about 2,400 participants in the United States, South America, Africa, and Asia. The result follows the drugmaker’s May comments that its SCORPIO-HR trial showed the pill failed to reduce common symptoms of the illness, compared to a placebo.
Japan gave the drug full approval in March this year. Although the government bought 2 million courses of the treatment during the pandemic, most of the supply was unused and set to be destroyed, media said.
Fair Use Notice
UNMC Global Center for Health Security staff curate publicly available news and information for educational and informational purposes. Brief excerpts of published articles may be displayed under principles of Fair Use, with credit and links provided to the source publications. All copyrights remain the property of their respective owners.